Jack E Henningfield - The Consciousness Library

Indigenous Knowledge Systems & Psychedelic Science: Towards Ethical and Reciprocal Collaboration.

Journal of psychopharmacology (Oxford, England) January 30, 2026 Veronica Magar, Marlena Robbins, Óscar Martín López Fernández Lobo Blanco et al. 1 citation

Indigenous Peoples have cultivated and protected natural psychoactive medicines through ceremony, kinship, and spiritual responsibility across generations, yet their long-standing contributions have often been marginalized through extractive research, commercialization, and policy exclusion. It is Indigenous communities that have stewarded and gained expertise working with psychoactive...

DOI: 10.1177/02698811251387104 Full text Psychedelic-assisted therapy Indigenous knowledge systems Indigenous governance Community-based research +6

Abuse potential assessment of novel central nervous system active and psychedelic substances for controlled substances act scheduling recommendations.

Journal of psychopharmacology (Oxford, England) 2026 Jack E Henningfield, Sandra D Comer, Matthew L Banks et al. 5 citations

Abuse potential assessment of drugs with central nervous system activity is a critical component of the development of new medications for regulatory filings for approval worldwide. These new drug applications typically include recommendations for scheduling status as a controlled substance, if scheduling is warranted. This commentary focuses on the approach and current issues related to...

DOI: 10.1177/02698811251378511 Full text Abuse potential Novel drugs Psychedelic

Roland R. Griffiths, psychopharmacology pioneer: Abuse liability, alcohol, nicotine, caffeine, benzodiazepines, and psychedelics.

Journal of psychopharmacology (Oxford, England) 2026 Jack E Henningfield, Frederick S. Barrett, Suzette M Evans et al.

This review provides an overview of Roland R. Griffiths' history of research, and his mentoring and collaborating approach to science that contributed to his impact in behavioral and neuropsychopharmacology and psychedelic medicines development. The approach was to summarize studies in his major domains of research, including preclinical and clinical abuse liability assessment science, alcohol,...

DOI: 10.1177/02698811251398801 Full text Abuse liability Caffeine Psychedelics Sedatives +1

Psychedelic research - Going global.

Journal of psychopharmacology (Oxford, England) December 1, 2025 David J Heal, Sharon L. Smith, Jack E Henningfield 1 citation

"Psychedelic research - Going global" is a Special Issue of the Journal of Psychopharmacology that has been compiled and published as a tribute to Dr. Roland R Griffiths in recognition of his pioneering and pivotal contribution to the field of psychedelic research. Dr. Griffiths was Professor in the Departments of Psychiatry and Neurosciences at Johns Hopkins University School of Medicine, and...

DOI: 10.1177/02698811251399575 Full text Clinical development Psychedelics Regulatory affairs Roland griffiths

Expanded access to psychedelic treatments: comparing American and Canadian policies.

Gen Psychiatr February 19, 2025 Jérémie Richard, Albert Garcia‐romeu, Jack E Henningfield 7 citations

The United States Food and Drug Administration’s (FDA’s) August 2024 determination that an additional phase III study will be required to consider the approval of midomafetamine for the treatment of post-traumatic stress disorder (PTSD) could delay the potential approval of this promising treatment by several years.

DOI: 10.1136/gpsych-2024-101894 Full text Psychedelic access Psychedelic policy Compassionate use

Psychedelics: Threshold of a Therapeutic Revolution

Neuropharmacology May 27, 2023 David J Heal, Sharon L. Smith, Sean J Belouin et al. 50 citations

This Special Issue of Neuropharmacology on psychedelics provides a timely and comprehensive update on progress following the previous Neuropharmacology Special Issue "Psychedelics: New Doors, Altered Perceptions". Remarkable advances have been made in basic and clinical research on psychedelics in the five years since 2018. It is partly based on the seminar series focused on psilocybin...

DOI: 10.1016/j.neuropharm.2023.109610 Psilocybin Anxiety Hallucinogen Psychotherapist

Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs

Neuropharmacology April 2, 2023 Farah Z Zia, Michael H. Baumann, Sean J Belouin et al. 28 citations

Chronic pain is a leading cause of disability, reduced productivity, healthcare seeking behavior, and a contributor to opioid overdose in the United States. For many people, pain can be satisfactorily managed by existing medicines and comprehensive psychosocial treatments. For others, available treatments are either ineffective or not acceptable, due to side effects and concerns about risks....

DOI: 10.1016/j.neuropharm.2023.109528 Existential distress LSD Psilocybin Magic mushrooms +11

Psychedelic Science, Contemplative Practices, and Indigenous and Other Traditional Knowledge Systems: Towards Integrative Community-Based Approaches in Global Health.

Journal of Psychoactive Drugs 2023 Julian Urrutia, Brian T Anderson, Sean J Belouin et al. 21 citations

As individuals and communities around the world confront mounting physical, psychological, and social threats, three complimentary mind-body-spirit pathways toward health, wellbeing, and human flourishing remain underappreciated within conventional practice among the biomedical, public health, and policy communities. This paper reviews literature on psychedelic science, contemplative practices,...

DOI: 10.1080/02791072.2023.2258367 Full text Indigenous Psychedelic science Community-based Contemplative practices +4

Psychedelic drug abuse potential assessment for new drug applications and controlled substance scheduling: A United States perspective

Journal of Psychopharmacology 2023 Jack E Henningfield, Judy Ashworth, David J Heal et al. 13 citations

Background: Psychedelics are an increasingly active area of research and pharmaceutical development. This includes abuse potential assessment to better understand their pharmacological mechanisms and effects and guide controlled substance regulation. Psychedelics pose challenges to abuse assessments to ensure valid, reliable, and generalizable outcomes and safe study conduct. Findings: Key...

DOI: 10.1177/02698811221140004 LSD MDMA Psilocybin Abuse potential assessment +9

Psychedelic-assisted psychotherapy to treat psychiatric and existential distress in life-threatening medical illnesses and palliative care.

Neuropharmacology September 15, 2022 S Ross, M Agrawal, Roland R. Griffiths et al. 69 citations

Psychiatric and existential distress commonly occur in advanced cancer and other serious, life-threatening or end-of-life medical illnesses and are associated with poor medical and psychiatric outcomes. Currently available treatment modalities in this patient population, including medication and psychotherapy, are limited in effectiveness, especially regarding existential distress. The lack of...

DOI: 10.1016/j.neuropharm.2022.109174 Full text Anxiety Depression Existential distress Psychedelic therapy +4

Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling

Neuropharmacology August 17, 2022 Jack E Henningfield, Marion A Coe, Roland R. Griffiths et al. 34 citations

New medicines containing classic hallucinogenic and entactogenic psychedelic substance are under development for various psychiatric and neurological disorders. Many of these, including psilocybin, lysergic acid diethylamide (LSD), and 3,4-methylenedioxymethamphetamine (MDMA) are Schedule I controlled substances of the United States Controlled Substances Act (US CSA), and similarly controlled...

DOI: 10.1016/j.neuropharm.2022.109220 Clinical study design Consciousness Controlled substance regulation Drug scheduling +9

Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines

Neuropharmacology August 13, 2022 Ingrid Donato, Veronica Magar, Sean J Belouin et al. 49 citations

There is mounting evidence suggesting psychedelic and entactogen medicines (namely psilocybin and 3,4-methylenedioxymethamphetamine [MDMA]), in conjunction with proper psychosocial support, hold the potential to provide safe, rapid acting, and robust clinical improvements with durable effects. In the US, both psilocybin and MDMA have been granted Breakthrough Therapy designations by the US Food...

DOI: 10.1016/j.neuropharm.2022.109214 Access to medicines Expanded access Internet privacy Public relations +1

Psychedelics - Re-opening the doors of perception.

Neuropharmacology August 23, 2018 David J Heal, Jack E Henningfield, Bruno G. Frenguelli et al. 7 citations

Psychedelics - Re-opening the doors of perception.

DOI: 10.1016/j.neuropharm.2018.08.024 Psychedelics certain compounds They Brain connectivity Rigid patterns +5

The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act

Neuropharmacology June 5, 2018 Matthew W. Johnson, Roland R. Griffiths, Peter S. Hendricks et al. 348 citations

This review assesses the abuse potential of medically-administered psilocybin, following the structure of the 8 factors of the US Controlled Substances Act (CSA). Research suggests the potential safety and efficacy of psilocybin in treating cancer-related psychiatric distress and substance use disorders, setting the occasion for this review. A more extensive assessment of abuse potential...

DOI: 10.1016/j.neuropharm.2018.05.012 Psilocybin Hallucinogen Substance abuse Pharmacology

Effects of marijuana smoking on subjective ratings and tobacco smoking.

Pharmacology, biochemistry, and behavior September 1986 R Nemeth-Coslett, J E Henningfield, M K O'Keeffe et al.

Multiple measures of tobacco cigarette smoking and subjective and physiological effect were collected during 90 minute test sessions in volunteer cigarette smokers who also had histories of recreational marijuana use. Before sessions, subjects smoked one marijuana cigarette (placebo or 1.29%, 2.84%, 4.00%) using a standardized puffing procedure. Each dose and placebo was given four times to...

DOI: 10.1016/0091-3057(86)90156-5 Full text

Papers